Tango Therapeutics IPO

Tango Therapeutics delivers the next generation of precision medicine to people with cancer that leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer.

Register for Details

For more details on financing and valuation for Tango Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Tango Therapeutics's ticker symbol?

TNGX

What is Tango Therapeutics's stock price?

3.78 as of 3/27/23

Tango Therapeutics Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
8/17/2020 Series B-1 $305.79MM $XXX.XX $XXX.XX
4/9/2020 Series B $170MM $XXX.XX $XXX.XX
3/30/2017 Series A $70.89MM $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Tango Therapeutics

Forge green plus iconForge green minus icon

What is Tango Therapeutics funding to date?

Tango Therapeutics has raised $166.88MM with the following series:
$70.89MM for Series A, $170MM for Series B, $305.79MM for Series B-1, $70.89MM for Series A, $170MM for Series B, $305.79MM for Series B-1.
Forge green plus iconForge green minus icon

When was Tango Therapeutics founded?

Tango Therapeutics was founded in 2014.